Found: 14
Select item for more details and to access through your institution.
Disturbed CXCR4/ CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 2, p. 240, doi. 10.1111/bjh.12883
- By:
- Publication type:
- Article
Comment on 'risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy'.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Comment on Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Perceptions and Motivation Regarding Performing Research in Physicians Specializing in Care for Older Adults Involved in a Mandatory Evidence-Based Medicine Training Study: A Mixed-Methods Study.
- Published in:
- Advances in Medical Education & Practice, 2022, v. 13, p. 217, doi. 10.2147/AMEP.S348735
- By:
- Publication type:
- Article
Comment on "Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase".
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 5, p. 919, doi. 10.1007/s00280-021-04345-8
- By:
- Publication type:
- Article
Comment on: Desensitization using PEGasparaginase in the era of commercially available Erwinia: A single‐institution report on efficacy, cost, and resource utilization.
- Published in:
- Pediatric Blood & Cancer, 2024, v. 71, n. 5, p. 1, doi. 10.1002/pbc.30935
- By:
- Publication type:
- Article
Comment on: Ocular abnormalities at diagnosis and after the completion of treatment in children and adolescents with newly diagnosed acute lymphoblastic leukemia.
- Published in:
- Pediatric Blood & Cancer, 2022, v. 69, n. 11, p. 1, doi. 10.1002/pbc.29700
- By:
- Publication type:
- Article
Comment on: "Premedication prior to PEG-asparaginase is cost effective in pediatric patients with acute lymphoblastic leukemia".
- Published in:
- 2022
- By:
- Publication type:
- Letter
Comment on "Comparison of hypersensitivity rates to intravenous and intramuscular PEGasparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review".
- Published in:
- 2021
- By:
- Publication type:
- Letter
Ammonia Levels Should Not Be Used as a Surrogate Marker of Levels of Asparaginase Activity in Acute Lymphoblastic Leukemia Patients.
- Published in:
- 2016
- By:
- Publication type:
- Letter
Native E. coli asparaginase upfront should be replaced by PEGasparaginase upfront in the treatment of pediatric patients with acute lymphoblastic leukemia.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 4, p. 809, doi. 10.1002/hon.2960
- By:
- Publication type:
- Article
No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
- Published in:
- Pediatric Blood & Cancer, 2013, v. 60, n. 2, p. 258, doi. 10.1002/pbc.24292
- By:
- Publication type:
- Article
Successful management of extreme hypertriglyceridemia in a child with acute lymphoblastic leukemia by temporarily omitting dexamethasone while continuing asparaginase.
- Published in:
- Pediatric Blood & Cancer, 2012, v. 58, n. 2, p. 317, doi. 10.1002/pbc.23266
- By:
- Publication type:
- Article
Comment on "Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL".
- Published in:
- 2021
- By:
- Publication type:
- Letter